Dimerization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase as an Antiviral Target
The DOI matches its Crossref record.
Abstract
Emergence of drug resistant strains of human immunodeficiency virus type 1 (HIV-1) is a major hindrance in the long-term treatment of HIV-1 infected individuals. Alternative strategies, including those directed to structural elements of viral targets, are needed to combat the growing acquired immune deficiency syndrome (AIDS) pandemic. The HIV-1 reverse transcriptase (RT) dimer interface, critical for dimer stability and catalytic function, is a novel target for designing new anti-HIV-1 drugs. Several existing RT inhibitors are known to impair polymerase function by destabilizing RT dimer stability and can serve as useful leads in this direction. Conversely, studies have shown that potent nonnucleoside reverse transcriptase inhibitors (NNRTIs) can enhance RT subunit interaction, which may contribute in part to the inhibitory effect of these drugs. Interface peptides are reported to suppress enzyme activity by interfering with active RT heterodimer formation. This review focuses on small molecule and peptide inhibitors that interfere with the formation of the active RT heterodimer and also discusses regions in the RT that are critical for RT dimerization that can be considered as potential targets for chemotherapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Le Grice, S. F. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.389056 · Cited by 73
Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase
Corona, A., Masaoka, T., Tocco, G., Tramontano, E., & Le Grice, S. F. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.178 · Cited by 54
Nikolenko, G. N., Delviks-Frankenberry, K. A., & Pathak, V. K. (2010) · Journal of Virology · doi:10.1128/jvi.01545-09 · Cited by 47
Retroviral RNase H: structure, mechanism, and inhibition
(2021) · The Enzymes · doi:10.1016/bs.enz.2021.07.007 · Cited by 13
Self-citation
Metadata
- Authors
- Srivastava, S., Sluis-Cremer, N., & Tachedjian, G.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-05-01
- Volume
- 12
- Issue
- 15
- Pages
- 1879-1894
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2144660961
- Cited by
- 30
- References
- 0
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dimerization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase as an Antiviral Target. https://app.cochat.ai/papers/10.2174/138161206776873590
- The paper
- Srivastava, S., Sluis-Cremer, N., & Tachedjian, G. (2006). Dimerization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase as an Antiviral Target. Current Pharmaceutical Design. https://doi.org/10.2174/138161206776873590
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.